Mukherjee Chandoshi, Mitra Arijit, Kumar N Ajith, Elsherbiny Samer, Lip Peck Lin
The Birmingham and Midland Eye Centre, City Hospital Dudley Road Birmingham, West Midlands B18 7QH, UK.
Open Ophthalmol J. 2015 Dec 31;9:177-80. doi: 10.2174/1874364101509010177. eCollection 2015.
Ranibizumab is a monoclonal antibody fragment that inhibits angiogenesis by inhibiting vascular endothelial growth factor A, used as a treatment for patients with wet aged-related macular degeneration (ARMD). Adverse effects from intravitreal Ranibizumab injections are well recognised. Macular hole formation following Ranibizumab injection is a complication that has been recently reported in few case reports. We present a larger case series of five patients, who developed full thickness macular holes (FTMH) after intravitreal Ranibizumab injections for treatment of wet ARMD that we were aware of between 2009 and 2013.
雷珠单抗是一种单克隆抗体片段,通过抑制血管内皮生长因子A来抑制血管生成,用于治疗湿性年龄相关性黄斑变性(ARMD)患者。玻璃体内注射雷珠单抗的不良反应已得到充分认识。雷珠单抗注射后黄斑裂孔形成是一种并发症,最近在少数病例报告中有所报道。我们报告了一个更大的病例系列,共5例患者,他们在2009年至2013年间因治疗湿性ARMD而接受玻璃体内雷珠单抗注射后出现了全层黄斑裂孔(FTMH)。